Breast Cancer (HER2+)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    ERBB2 (HER2) Amplification 20 Trastuzumab (HER2 inhibitor) (FDA approved):
    • Phase 3: Single agent, first line, RR 26% (20)
    • Phase 3, with chemotherapy: RR 50% vs. 32% for chemo alone, PFS 7.4 vs. 4.6 mo (21)
    • Phase 3, with lapatinib, neoadjuvant: RR 51% vs. 30% with trastuzumab alone vs. 24% with lapatinib alone (22)
    Lapatinib (dual HER2/EGFR inhibitor) (FDA approved):
    • Phase 2: Single agent, after trastuzumab, RR 12.6% (23)
    • Phase 3, with trastuzumab: PFS
    Other topics in Targets by Organ Site